aetna and cvs seek to rip out your life, take your money and leave you
impaired
if you cannot get bcg from the departments of health and the like you might resort to the plan b of your choice
the angel of death laughs at those who cannot read write or think or believe money is all that there is to life
death to those who will kill you? self defense?
may aetna and cvs burn in hell. and provide there goods to north korea
the great one is either a woman or the italian g ristori
Updates from the Faustman Laboratory at Massachusetts General Hospital.
|
|
 |
December 1, 2017
Dear Friends,
We had another great year at the Faustman lab. The Phase II BCG trial is fully enrolled with 150 participants who have type I diabetes. All 150 of these volunteers have received at least 1 dose of BCG or placebo. In addition, the participants from the Phase I study who originally received placebo, but were then vaccinated with BCG as part of a crossover study, are already yielding interesting results, which we will be able to share soon.
This year, we also presented new mechanistic data on BCG and how it alters the immune system at the 77th Scientific Sessions of the American Diabetes Association (ADA) as well as the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD). The positive feedback and media coverage was overwhelming. In October, we convened the third international conference on BCG and autoimmune disease. Researchers from around the globe shared updates on their research on BCG. Elsevier, a scientific publishing company, will be issuing a book based on the proceedings in 2018.
BCG is a generic vaccine that holds the promise of an affordable treatment option for type 1 diabetic patients of all means. As you know, we are operating outside the traditional funding models for clinical trials because BCG is a generic drug. All of our funding comes from private philanthropies and individuals who are impacted by the disease. We are the "open source" approach to clinical trials -- "a clinical trial by the people for the people".
Enrolling the Phase II trial was a big step, but we have a lot of work to do. In order to meet our goal of bringing BCG to market with an FDA approved indication for type I diabetes, we need the funding to track patients in the trial for the next 5 years. We are also actively planning and enrolling new patient groups. Anything you can do to help us meet our fundraising goals and turn our full attention back to the research is appreciated.
Enclosed please find our annual newsletter on our website www.faustmanlab.org. Please click on the News Tab then scroll down to Lab Newsletter to find the Fall 2017 newsletter.
Thank you so much for all of your support!
Denise L. Faustman, MD, PhD
|
|
|
|
Faustman Lab at Mass General
Massachusetts General Hospital
Charlestown, Massachusetts 02129
diabetestrial@partners.org
617-726-4084
|
|
|
|
|
|
|
|
No comments:
Post a Comment